Epidemiological phenotypic characteristics of vaginal yeasts at the Comoros.

The aim of the prospective, descriptive survey conducted in Moroni, Comoros was to establish the distribution of vulvovaginal mycoses in pregnant and symptomatic women and to study the epidemiological characteristics of the yeast isolates. All isolated strains were epidemiologically evaluated by phenotypical methods. Three phenotypic epidemiological studies were performed by morphotyping methods (including the colour reaction according to Quindòs et al. and structural morphotypes as described by Soll), by determination of phospholipase and by chemosensitivity evaluation according to the Clinical and Laboratory Standards Institute approved standard. Out of 253 women, 108 were found positive for yeast culture (42.7%). Fungal identification results showed that 61.6% was Candida albicans and 28.6%C. sake (32/112). Candida sake was a frequent vaginal inhabitant.

Geographical distribution of HIV-1 group O viruses in Africa.

OBJECTIVE: To determine to what extent HIV-1 group O strains are present in different African countries. MATERIALS AND METHODS: A total of 14,682 samples of sera from a range of patients from 12 different African countries were tested. All the sera were tested with an enzyme-linked immunosorbent assay (ELISA) using a combination of V3 peptides from ANT-70 and MVP-5180. Samples reactive in ELISA were retested in a line immunoassay (LIA-O). Samples reactive in ELISA were also retested with an in-house Western blot to determine the presence of antibodies to gp120 of HIV-1 ANT-70. Polymerase chain reaction was performed on HIV-1 group O and group O indeterminate sera. RESULTS: Of all the sera samples tested, only 19 sera had antibodies to group O V3 peptides exclusively and 46 were indeterminate for group O infection in LIA-O. The highest prevalence of HIV-1 group O infection among HIV-positive sera was observed in Cameroon (2.1%) and neighbouring countries, 1.1% in Nigeria and 0.9% in Gabon. The lowest rates were seen in west Africa: 0.07% in Senegal, 0.14% in Togo, 0.16% in Chad and 0.3% in Niger. Group O sera were observed in almost all the population categories tested. The ANT-70 V3 peptide in LIA-O was reactive with all of the sera considered to be HIV-1 group O antibody positive by LIA, versus 78.9% for the MVP-5180 peptide. Thirteen out of 19 group O samples of sera were tested in PCR. Eight samples were identified as group O by specific group O pol and/or V3 primers; in the remaining five samples no HIV RNA could be detected. Of the indeterminate sera samples, two were identified as group O. CONCLUSION: In eight of the 12 countries tested, antibodies to group O viruses were identified. Numbers of HIV-1 group O viruses are low. Their presence is not restricted to Cameroon and neighbouring countries but can also be found in west and south-east Africa.

PIP: An enzyme-linked immunosorbent assay (ELISA), using a combination of V3 peptides and ANT-70 and MVP-5180, was used to test 14,682 sera samples from people living in Burkina Faso, Burundi, Cameroon, Chad, Congo, Gabon, Mali, Niger, Nigeria, Senegal, Togo, and Zambia to examine the geographic spread of HIV-1 group O viruses in Africa. An in-house Western blot and a line immunoassay (LIA-O) were used to detect the presence of antibodies to gp120 of HIV-1 ANT-70 of samples reactive in ELISA and then a polymerase chain reaction (PCR) on HIV-1 group O and group O indeterminant sera. HIV-1 group O antibodies were present in 8 countries (Cameroon, Chad, Gabon, Niger, Nigeria, Senegal, Togo, and Zambia). Among these 8 countries, the prevalence of HIV-1 group O sera ranged from 2.1% in Cameroon to 0.07% in Senegal. Cameroon and its neighboring countries had a higher prevalence than the West African countries (0.9-2.1% vs. 0.07-0.3%) and Zambia. HIV-1 group O virus was more or less evenly distributed among the population groups tested. The ANT-70 V3 peptide in LIA-O had a higher reactivity rate with HIV-1 group O sera than MVP-5180 V3 peptide in LIA-O (100% vs. 78.9%). 8 of the 13 samples tested in PCR were identified as group O by specific group O pol and/or V3 primers. Among the remaining 5 indeterminant sera samples, 2 were identified as group O. Prospective studies are needed to monitor the true prevalence of HIV-1 group O viruses in Cameroon, its neighboring countries, and West Africa. They are also needed to determine the risk factors associated with group O infection. Monitoring these viruses will allow adaptation of HIV testing strategies for blood screening and serodiagnosis if required.

[AIDS and HIV infection in the Federal Islamic Republic of Comores (1988-1995)]. / SIDA et infection à VIH en République Fédérale Islamique des Comores (1988-1995).

Since 1991 AIDS and HIV infection in the Federal Islamic Republic of the Comoros have been monitored through a network of sentinel sites including predetermined target populations. In all cases seropositivity for HIV was confirmed by western blotting after two ELISA screening tests. AIDS was diagnosed on Bangui clinical criteria and positive western blotting results. As of June 30, 1996, the cumulative number of AIDS cases reported to the World Health Organization was 7 for a prevalence of 1.4 per 100000 inhabitants. The prevalence of HIV antibodies has remained at less than 1% in target populations, i.e. women undergoing prenatal examinations, patients with newly diagnosed tuberculosis, blood donors, and patients presenting sexually transmitted diseases (STD). This low stable prevalence rate which is similar to those reported in other Indian Ocean countries is in sharp contrast with the high incidence of syphilis and STD in the region.

A predictable comeback: the second pandemic of infections caused by Neisseria meningitidis serogroup A subgroup III in Africa, 1995.

Between 14 January and 4 April 1995 we isolated and characterized 44 meningococcal strains in Cameroon, Chad, Niger, and Burkina Faso; among these was the strain A:4:P1.9/clone III-1, which was involved in the second meningitis pandemic. This isolate was found in the clonal form in Niger and strains of the ET-37 complex were also found in the other three study countries, but apparently did not cause epidemics. One strain (Y:2a:P1.2,5 (ET-37 complex)) was isolated in January 1995 and another (A:4:P1.9) in March 1995 in Garoua (Cameroon). Eight strains were isolated in Moundou (Chad) between January and April 1995: the A:4:P1.9/clone III-1 (1 strain); members of the ET-37 complex (Y:2a:P1.2,5 (4 strains), Y:NT:P1.2,5 (1 strain), and Y:2a:-(1 strain)); and serogroup X (1 strain). In Niger, 31 strains were isolated between February and April 1995 from different regions. All were A:4:P1.9/clone III-1; between November 1994 and April 1995 there were 23814 cases of meningitis reported of which 2227 resulted in death. Three strains were isolated in Burkina Faso in April 1995: two were Y:2a:P1.2,5 (ET-37 complex) and one was A:4:P1.9/clone III-1. Thus in 1995 the epidemic and invasive strain (A:4:P1.9/clone III-1) responsible for the second pandemic was present in the four countries (Cameroon, Chad, Niger and Burkino Faso) that make up the area frequently affected by such epidemics and where cases are generally reported during the dry season.

[Anemia in infants less than 1 year old in Moundou, Chad: prevalence and etiology]. / L'anémie de l'enfant de moins de un an à Moundou, Tchad: prévalence et étiologies.

In order to evaluate the prevalence of anemia in infants under one year of age and ascertain the main etiologic factors, a survey was conducted in Moundou, Chad at the end of the rainy season. Tests were performed in 144 infants to determine hemoglobin levels, mean erythrocyte volume, transferrin saturation coefficient, serum iron level, Plasmodium positivity on blood smears, and nutritional status according to GOMEZ. Using the criteria defined by the World Health Organization, 139 infants were diagnosed as anemic including 19 cases classified as severe (hemoglobin level less than 5 g/dl). In addition, 32 of the 141 infants studied (22.7%) presented iron deficiency confirmed by two positive indicators. Serology demonstrated malaria in 45% of infants. Mean hemoglobin levels were significantly lower in infants with positive blood smears and this lowering increased the higher serum parasite levels. Nutritional status was directly correlated with hemoglobin level. This data suggests that malaria plays a major etiologic role in anemia in infants particularly severe anemia. This finding justifies use of antimalarial chemoprophylaxis in infants and the Centers for the Extended Vaccination Program provide the framework.